BerGenBio ASA (OSL:BGBIO)

Market Cap	68.40M
Revenue (ttm)	848.00K
Net Income (ttm)	-139.28M
Shares Out	39.09M
EPS (ttm)	-3.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	231,063
Average Volume	137,336
Open	1.722
Previous Close	1.750
Day's Range	1.700 - 1.750
52-Week Range	1.450 - 16.000
Beta	1.18
RSI	40.79
Earnings Date	Apr 29, 2025

About BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: Oslo Børs
• Ticker Symbol: BGBIO

Financial Performance

In 2024, BerGenBio ASA's revenue was 848,000, an increase of 139.55% compared to the previous year's 354,000. Losses were -139.28 million, -26.85% less than in 2023.